Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Disorders of Consciousness
NCT05343507Phase 3Recruiting
- Sponsor
- University of Liège
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in disorders of consciousness (DoC) comparing Ketalar with Placebo (2 arms). Primary endpoints: Emergence of new conscious behaviours and Higher brain complexity. Started May 2022; status: recruiting.
02
Drugs
ketamine
03
Conditions
disorders of consciousness (DoC)
Beyond the preview
Go deeper on NCT05343507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343507.